Key Success Factors in Pricing, Reimbursement and Market Access

 Published On: Sep, 2017 |  Published By: FirstWord | Format: PDF
Request Free Sample
Key Success Factors in Pricing, Reimbursement and Market Access

Novel pricing and reimbursement models are shaping the uptake of medicines. Yet the market access goalposts keep being moved as payer policies, needs and attitudes evolve. In an ever-changing market access landscape how can pharma companies renew or upgrade their commercialisation strategies?

Key Success Factors in Pricing, Reimbursement and Market Access investigates innovative pharma-payer contracts and other market access strategies to provide actionable insights on the most appropriate approach to pricing and reimbursement. By benchmarking 10 leading pharma companies’ strategies the report identifies 13 key success factors for delivering progressive pricing, reimbursement and market access outcomes.

Discover on this page…

-The executive summary below, taken directly from the report, presents key findings from the research
-The rigorous research objectives and methodologies employed to produce the report
-Detailed report contents
-Why this report is important to you

1. Executive Summary

Payers and healthcare authorities are maximising their ability to influence and control treatment access. They do so by limiting coverage, introducing or changing product evaluation criteria, and exerting pressure on drug manufacturers to contain prices. Healthcare cost containment efforts across the globe have driven interest in innovative pharma-payer contracting models, such as risk-based agreements. However, these models are only one component of the market access solution. Furthermore, drug manufacturers do not yet possess adequate knowledge of the best techniques to implement such agreements with confidence. Pharmaceutical companies instead require a much broader range of pricing, reimbursement and market access strategies to ensure a sustainable trajectory both for currently marketed products and those that are still in the pipeline.

So, how can access to medicines be optimised? An analysis of the industry reveals a lack of best practice guidelines for pricing, reimbursement and market access in the new healthcare landscape. With the objective of presenting readers with key success factors for best practice, this report benchmarks the pricing, reimbursement and market access strategies and payer agreements of the following 10 pharma companies:

-AstraZeneca
-Bayer
-Celgene
-Eli Lilly
-GlaxoSmithKline
-Johnson & Johnson
-Merck & Co
-Merck Group
-Novartis
-Top 50 pharmaceutical company

Analysis of the case studies on the 10 pharma companies revealed that some of the common themes among pharma companies with regard to pricing, reimbursement and market access strategy include: adopting unique payer engagement methods to accomplish various objectives, such as developing improved understanding of payers to better approach them; leveraging existing payer connections; acquiring additional payer input; communicating product value; and, negotiating the price and coverage of medicines.

The report revealed comparisons between the payer structures in Europe, the US and emerging markets, emphasising the need for drug manufacturers to understand and address specific payer needs. The factors considered when deciding on the design, terms and execution of innovative payer contracts are also discussed.

The challenges to pricing, reimbursement, and market access also comprised a key topic. The challenges identified by key opinion leaders in this report include the complex implementation of pharma-payer contracts, the impact of reference pricing, the lack of internal alignment, and the lack of payer trust in pharma. Furthermore, issues around pricing limits placing constraints on investments in specialty medicines and other innovative products that are typically associated with high prices were discussed.

An analysis of the 10 pharma company case studies, together with insights from nine experts, reveals 13 key success factors that can help overcome the challenges outlined in the report. These include:

-Develop a deep understanding of the market
-Establish criteria for the selection of payers to partner with
-Go down to the local or regional payer level
-Research competitor products
-Adopt a mixture of pricing schemes
-Initiate early and continuous payer engagement
-Conduct early payer conversations for specialty medicines
-Talk directly with the decision-makers at payer organisations
-Select the most appropriate endpoints and outcomes to fit valuation frameworks
-Generate evidence
-Know your product
-Be patient-centric
-Collaborate internally and externally

These key success factors were explored within the case studies to gain further insight into the function and degree of their role within market access. Insights and best practices are provided on how to utilise price to design patient access schemes and optimise opportunities for innovation. These factors also reveal how drug manufacturers leverage evidence, internal teams, stakeholder partnerships and technology to support coverage and treatment access.

2. Research Methodology and Objectives

The information within this report was gathered from primary and secondary sources, including a comprehensive literature review and in-depth interviews (n=10) with individuals employed at leading pharma and healthcare consulting companies in roles that have responsibilities for pricing, reimbursement, market access, and payer strategy.

The interviews were conducted in March and April 2017 and explored: how pricing can be designed to establish balance between patient access, innovation, and affordability; how payers can be engaged and interacted with across the drug life cycle; how the involvement of other stakeholders can be leveraged to promote market access; key success factors; case studies; and, future opportunities.

Key questions explored in this report include

-What are the key considerations in crafting pricing, reimbursement, and market access solutions?
-What top strategies for acquiring payer input on price can pharma companies employ throughout the different clinical development stages?
-What are the criteria for selecting the payer/s to contract with?
-What economic modelling methods, negotiation techniques, and price optimisation strategies are being utilised in payer contracting?
-What are the internal roles involved in shaping a pricing contract with a payer?
-Which internal and external stakeholders should be leveraged during planning and implementation, and how?
-How can payer engagement be integrated throughout the contract life-cycle?
-In contracting with payers, how should evidence and value generation be approached?
-In contracting, what are the required data strategies, analytical methods, and expertise?
-How can patient-centricity and customer experience be reflected in price and contracting?
-What is the participation of external stakeholders - patients, patient advocacy groups, clinicians, and KOLs - in shaping pricing contracts with payers?
-How can companies adopt a local-based focus when it comes to pricing and contracting?
-What are the barriers or challenges unique to pricing and how can these barriers be overcome?
-What is the significance or the role of payer contracting to pharma's business now and in the future?
-What are the key success factors in pricing, reimbursement, and market access contracting?
1. Executive Summary
2. Research Objectives
3. Experts interviewed
4. The uncertainty of market access
4.1 Cost containment and the need for evidence of medicine value versus patient access to treatments
4.2 The impact of cost containment on product innovation
4.3 Payer contracting: a viable solution for pharma’s market access problems
5. Companies that set the benchmark for pricing, reimbursement, and market access strategy
5.1 Key Findings
5.2 Case Studies
5.2.1 GlaxoSmithKline (GSK)
5.2.2 Eli Lilly
5.2.3 Johnson and Johnson (J&J)
5.2.4 AstraZeneca
5.2.5 Novartis
5.2.6 Merck Group
5.2.7 Company X
5.3 Companies with emerging innovative pricing and reimbursement strategies
5.3.1 Celgene
5.3.2 Merck & Co.
5.3.3 Bayer
5.3.4 Common Themes
5.3.5 Common hurdles to creating payer contracts
5.3.6 SWOT Analysis
6. Key Success Factors
6.1 Key Findings
7. The future of payer contracting
7.1 Payer contracting to remain a fixture, but will evolve to market influence
7.2 Pharma, payers, and regulators as partners
7.3 More complex, innovative pricing schemes on the horizon
7.4 Viewing the total cost of care
8. Conclusion
9. Appendix

If the above report does not have the information suitable for your business, we can provide custom research that can be lucrative for your business or enhance your profession.